Xoma | XOMA - Operating Expenses

Stock Price
41.75
Daily Change
-0.25 -0.60%
Monthly
5.40%
Yearly
54.69%
Q2 Forecast
40.91

Xoma reported $22.84M in Operating Expenses for its fiscal quarter ending in September of 2024.





Operating Expenses Change Date
AbbVie USD 10.27B 538M Mar/2026
Agenus USD -221.22M 241.03M Mar/2026
Agios Pharmaceuticals USD 130.77M 10.77M Mar/2026
Ardelyx USD 120.12M 14.46M Dec/2025
aTyr Pharma USD 85.61M 58.67M Dec/2025
BioMarin Pharmaceutical USD 636.56M 39.61M Mar/2026
Celldex Therapeutics USD 456.23M 368.95M Mar/2026
Curis USD 9.02M 23.01M Dec/2025
Eli Lilly USD 10.02B 285M Mar/2026
Emergent BioSolutions USD 555.9M 242.7M Jun/2023
Incyte USD 5.62B 4.5B Mar/2026
MacroGenics USD 21.2M 32.13M Mar/2026
Novartis USD 9.29B 507M Mar/2026
Novartis USD 9.8B 23M Dec/2025
Pfizer USD 90.1B 77.19B Mar/2026
Prothena USD 27.23M 14.95M Dec/2025
Regeneron Pharmaceuticals USD 31.42B 28.44B Mar/2026
Xoma USD 22.84M 1.67M Sep/2024